GeneDx to Participate in Upcoming Investor Conferences in June
24 mai 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will...
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
23 mai 2023 07h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will...
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
22 mai 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a...
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
09 mai 2023 16h05 HE
|
GeneDx Holdings Corp.
Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue included $22.4 million in whole exome testing,...
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
04 mai 2023 07h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced the availability of its...
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
03 mai 2023 13h06 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification...
GeneDx Announces Reverse Stock Split
28 avr. 2023 08h10 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of...
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
18 avr. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
03 avr. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K....
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
20 mars 2023 08h45 HE
|
GeneDx Holdings Corp.
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four YearsInitial Data and...